NfL is a biomarker of neuron/axon nerve damage/death. Higher levels predict significant poor outcomes, if NfL levels are lowered, it will show ATH434 works to preserve this, and protects these nerves/cells from dying, therefore reducing symptoms.
In the 202 study, treated pts has a 2.4% increase with treatment compared to 17% increase, but remember they were also late stage patients, here we are dealing with newly diagnosed, so hopefully we have no NfL readings or significantly reduced levels to those on placebo.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)